<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02640508</url>
  </required_header>
  <id_info>
    <org_study_id>CTMS 15-2139</org_study_id>
    <secondary_id>HSC20150891H</secondary_id>
    <nct_id>NCT02640508</nct_id>
  </id_info>
  <brief_title>Eribulin and Lenvatinib in Advanced Solid Tumors</brief_title>
  <official_title>Phase II Trial of Eribulin and Lenvatinib in Advanced Solid Tumors (CTMS# 15-2139)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Virginia G. Kaklamani</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eisai Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>The University of Texas Health Science Center at San Antonio</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The overall purpose of this study is to determine the overall response rate, efficacy and&#xD;
      safety of the combination of eribulin and Lenvatinib.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a phase II clinical trial of the combination of eribulin, and Lenvatinib. A cycle&#xD;
      will be defined as 21 days. Eribulin will be given on days 1 and 8 of each cycle. Lenvatinib&#xD;
      will be given daily during each cycle.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>May 2016</start_date>
  <completion_date type="Anticipated">November 2021</completion_date>
  <primary_completion_date type="Actual">November 24, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall response rate of lenvatinib and eribulin</measure>
    <time_frame>The overall response rate will be assessed after two cycles of therapy (1 cycle = 3 weeks) until the date of first documentation of disease progression or death (whichever occurs first) over an average of 18 months.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Lenvatinib and eribulin toxicities will be graded using NCI CTCAE version 4.03</measure>
    <time_frame>Safety will be evaluated from the time of registration until 30 days after last dose of treatment, resolution of the related AE or death.</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Cancer</condition>
  <condition>Solid Tumor</condition>
  <arm_group>
    <arm_group_label>Combination Eribulin and lenvatinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eribulin will be given on days 1 and 8. Lenvatinib will be given daily in each 28 day cycle.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Eribulin</intervention_name>
    <description>Will be given by I.V. at 1.4 mg/m2 on day 1 and day 8.</description>
    <arm_group_label>Combination Eribulin and lenvatinib</arm_group_label>
    <other_name>Halaven</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lenvatinib</intervention_name>
    <description>Will be taken orally at 20-24 mg daily in each 21 day cycle.</description>
    <arm_group_label>Combination Eribulin and lenvatinib</arm_group_label>
    <other_name>Lenvima</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Stage IV breast cancer, stage IV NSCLC (Non-Small Cell Lung Cancer) (, stage IV&#xD;
             sarcoma&#xD;
&#xD;
          -  ECOG (Eastern Cooperative Oncology Group) PS (Performance Status) 0-2&#xD;
&#xD;
          -  Measurable disease&#xD;
&#xD;
          -  No more than 4 prior chemotherapeutic regimens for metastatic disease&#xD;
&#xD;
          -  Patients must be &gt;/= 18 years.&#xD;
&#xD;
          -  Patients may not have received eribulin or lenvatinib previously&#xD;
&#xD;
          -  Patients must have a life expectancy of greater than 12 weeks.&#xD;
&#xD;
          -  Patients may have had a prior diagnosis of cancer if it has been &gt; 5 years since their&#xD;
             last treatment and are considered free of disease.&#xD;
&#xD;
          -  Patients must have normal organ and marrow function as defined below:&#xD;
&#xD;
        Leukocytes ≥ 3,000/uL Absolute neutrophil count ≥ 1,500/uL Platelets ≥ 100,000/uL Child&#xD;
        Pugh score ≤ 10 Patients must be able to swallow and retain oral medication. All patients&#xD;
        must have given signed, informed consent prior to registration on study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Women who are pregnant or lactating are not eligible for study treatment.&#xD;
&#xD;
          -  Patients who are undergoing concomitant radiotherapy are NOT eligible for&#xD;
             participation.&#xD;
&#xD;
          -  Patients who are receiving any other investigational agents or concurrent anticancer&#xD;
             therapy are NOT eligible for participation. Previous systemic treatment and/or&#xD;
             radiation therapy is allowed with a 14 day washout period prior to registration.&#xD;
&#xD;
          -  Lesions that have been radiated previously cannot be considered target lesions&#xD;
&#xD;
          -  Prior treatment related side effects must have resolved to &lt; Grade 2 severity per&#xD;
             Common Terminology Criteria for Adverse Events (CTCAE version 4.03), except alopecia&#xD;
             and infertility.&#xD;
&#xD;
          -  Patients who are taking any herbal (alternative) medicines are NOT eligible for&#xD;
             participation. Patients must be off any such medications by the time of registration.&#xD;
&#xD;
          -  Patients with known brain metastases are NOT eligible for participation unless the&#xD;
             brain metastases are treated (either with surgical excision, stereotactic radiosurgery&#xD;
             or radiotherapy) and have been stable for at least 4 wks per MR performed, the patient&#xD;
             is asymptomatic and has discontinued corticosteroids if taken for that purpose.&#xD;
&#xD;
          -  Patients with any of the following conditions or complications are NOT eligible for&#xD;
             participation:&#xD;
&#xD;
               1. GI tract disease resulting in an inability to take oral medication&#xD;
&#xD;
               2. Malabsorption syndrome&#xD;
&#xD;
               3. Require IV alimentation&#xD;
&#xD;
               4. History of prior surgical procedures affecting absorption&#xD;
&#xD;
               5. Uncontrolled inflammatory GI disease (e.g., Crohn's, ulcerative colitis).&#xD;
&#xD;
               6. Hypersensitivity of any of the components of eribulin or lenvatinib&#xD;
&#xD;
               7. History of significant neurological ( no neuropathy more than grade 2) or&#xD;
                  psychiatric disorders&#xD;
&#xD;
               8. Significant non neoplastic liver disease (Cirrhosis, active chronic hepatitis)&#xD;
&#xD;
               9. Immunocompromised subjects, including patients with human immunodeficiency virus&#xD;
&#xD;
              10. Significant non neoplastic renal disease&#xD;
&#xD;
              11. Active infection requiring systemic therapy.&#xD;
&#xD;
              12. Significant cardiovascular impairment: history of congestive heart failure&#xD;
                  greater than New York Heart Association (NYHA) Class II, uncontrolled arterial&#xD;
                  hypertension, unstable angina, myocardial infarction or stroke within 6 months of&#xD;
                  the first dose of study drug; or cardiac arrhythmia requiring medical treatment&#xD;
&#xD;
              13. Prolongation of QTc interval to more than 480 milliseconds when electrolyte&#xD;
                  balance is normal&#xD;
&#xD;
              14. Major surgery within 4 weeks prior to first dose of the study drug.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Virginia Kaklamani, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Texas Health Science Center San Antonio</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cancer Therapy and Research Center University of Texas Health Science Center San Antonio</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>November 26, 2015</study_first_submitted>
  <study_first_submitted_qc>December 22, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 29, 2015</study_first_posted>
  <last_update_submitted>March 1, 2021</last_update_submitted>
  <last_update_submitted_qc>March 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>The University of Texas Health Science Center at San Antonio</investigator_affiliation>
    <investigator_full_name>Virginia G. Kaklamani</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lenvatinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

